HomeCompareCCLLF vs ABBV

CCLLF vs ABBV: Dividend Comparison 2026

CCLLF yields 1.51% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CCLLF wins by $949.8K in total portfolio value· pulled ahead in Year 6
10 years
CCLLF
CCLLF
● Live price
1.51%
Share price
$63.09
Annual div
$0.95
5Y div CAGR
78.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.05M
Annual income
$755,152.09
Full CCLLF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CCLLF vs ABBV

📍 CCLLF pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCCLLFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CCLLF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CCLLF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CCLLF
Annual income on $10K today (after 15% tax)
$128.01/yr
After 10yr DRIP, annual income (after tax)
$641,879.28/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CCLLF beats the other by $620,823.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CCLLF + ABBV for your $10,000?

CCLLF: 50%ABBV: 50%
100% ABBV50/50100% CCLLF
Portfolio after 10yr
$577.3K
Annual income
$389,961.92/yr
Blended yield
67.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CCLLF
No analyst data
Altman Z
4.0
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CCLLF buys
0
ABBV buys
0
No recent congressional trades found for CCLLF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCCLLFABBV
Forward yield1.51%3.06%
Annual dividend / share$0.95$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR78.7%40.6%
Portfolio after 10y$1.05M$102.3K
Annual income after 10y$755,152.09$24,771.77
Total dividends collected$1.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CCLLF vs ABBV ($10,000, DRIP)

YearCCLLF PortfolioCCLLF Income/yrABBV PortfolioABBV Income/yrGap
1$10,969$269.13$11,550$430.00$581.00ABBV
2$12,230$493.03$13,472$627.96$1.2KABBV
3$14,004$918.04$15,906$926.08$1.9KABBV
4$16,740$1,755.64$19,071$1,382.55$2.3KABBV
5$21,417$3,504.91$23,302$2,095.81$1.9KABBV
6← crossover$30,405$7,488.83$29,150$3,237.93+$1.3KCCLLF
7$50,289$17,755.90$37,536$5,121.41+$12.8KCCLLF
8$102,856$49,047.25$50,079$8,338.38+$52.8KCCLLF
9$277,595$167,538.31$69,753$14,065.80+$207.8KCCLLF
10$1,052,178$755,152.09$102,337$24,771.77+$949.8KCCLLF

CCLLF vs ABBV: Complete Analysis 2026

CCLLFStock

CCL Industries Inc. engages in manufacture and sale of labels, and provides media and software solutions. It operates through four segments: CCL, Avery, Checkpoint, and Innovia. The CCL segment offers pressure sensitive and extruded film materials for decorative, instructional, security, and functional applications in the consumer packaging, healthcare, chemicals, consumer durables, electronic device, and automotive markets. This segment also provides extruded and labeled plastic tubes, aluminum aerosols and specialty bottles, folded instructional leaflets, precision decorated and die cut components, electronic displays, polymer banknote substrate, and other complementary products and services. The Avery segment offers printable media products, including address and shipping labels, marketing and product identification labels, indexes and dividers, business cards, and name badges supported by customized software solutions; and organizational products, such as binders, sheet protectors, and writing instruments. This segment also provides direct to consumer digitally imaged media products, such as labels, business cards, name badges, and family oriented identification labels supported by unique web-enabled e-commerce URLs. The Checkpoint segment offers technology-driven loss-prevention, inventory management, and labelling solutions, including radio frequency and radio-frequency identification solutions to retail and apparel industries. The Innovia segment provides specialty, high-performance, multi-layer, and surface engineered biaxially oriented polypropylene films for pressure sensitive label materials, flexible packaging, and consumer packaged goods industries. It operates in Canada, the United States, Puerto Rico, Latin America, Europe, Asia, Africa, and Australia. The company was founded in 1951 and is headquartered in Toronto, Canada.

Full CCLLF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CCLLF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CCLLF vs SCHDCCLLF vs JEPICCLLF vs OCCLLF vs KOCCLLF vs MAINCCLLF vs JNJCCLLF vs MRKCCLLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.